Business Context and Reporting Period
Indaptus Therapeutics, Inc. filed a Form 8-K dated August 3, 2021, reporting completion of its business combination with Decoy Biosystems, Inc. The transaction was treated as a reverse acquisition for accounting purposes, with Decoy as the accounting acquirer. Indaptus is a preclinical biotechnology company developing a patented, systemically administered anti-cancer and anti-viral immunotherapy.
Following the merger, the company changed its name from Intec Parent, Inc. to Indaptus Therapeutics, Inc. Its common stock began trading on Nasdaq under the ticker INDP on August 4, 2021.
Key Financial and Capitalization Matters
- The filing does not provide revenue, net income, operating cash flow, cash balances, margins, debt balances, or other periodic financial statement metrics.
- The company completed a private placement of a pre-funded warrant for up to 2,727,273 common shares and a warrant for up to 2,727,273 common shares.
- Gross proceeds were approximately $29.9 million, or approximately $30.0 million assuming full exercise of the pre-funded warrant, before placement-agent fees and other offering expenses.
- Immediately after the merger, 5,405,963 common shares were outstanding, excluding shares issuable upon exercise of outstanding warrants and options. Pre-merger Decoy shareholders owned approximately 65.6% and pre-merger Intec Israel shareholders approximately 34.4%.
- Assuming full exercise of the pre-funded warrants, 8,133,236 common shares would be outstanding.
- The filing does not state the company’s post-closing cash balance or liquidity runway.
Material Changes Versus the Prior Comparable Period
- Decoy became a wholly owned subsidiary and its business became the company’s principal business.
- Intec Israel became a wholly owned subsidiary following a domestication merger completed July 27, 2021.
- Nasdaq filed a Form 25 on August 3, 2021, to delist and deregister Intec Israel’s ordinary shares; the delisting was expected to become effective 10 days after filing.
- The company’s historical financial statements will be those of Decoy, the accounting acquirer, including Decoy’s audited December 31, 2020 and 2019 financial statements.
- The company expected to replace Kesselman & Kesselman, a PwC member firm, with Haskell & White LLP as independent registered public accounting firm, subject to Audit Committee approval and a subsequent SEC filing.
- The board expanded to eight directors, and Michael Newman, Ph.D. became Chief Scientific Officer. Jeffrey Meckler, Nir Sassi, and Walt Linscott continued as Chief Executive Officer, Chief Financial Officer, and Chief Business Officer, respectively.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The filing provides no quantitative revenue, earnings, clinical, or cash-flow guidance.
- As a preclinical biotechnology company, Indaptus remains subject to the substantial development, regulatory, financing, and commercialization risks typical of early-stage drug-development companies.
- The private placement securities create potential future dilution. Outstanding warrants, options, and the 2021 Stock Incentive Plan may also increase the share count.
- The 2021 Stock Incentive Plan authorizes up to 1,864,963 shares, with potential annual increases from 2022 through 2024 of the lesser of 3% of outstanding shares or a smaller board-determined amount.
- New executive arrangements include annual base salaries of $540,000 for the CEO, $425,000 for the Chief Scientific Officer, and $405,000 for the Chief Business Officer. The CFO consulting arrangement provides for monthly payments of $31,500.
- Employment agreements include severance benefits, enhanced change-in-control severance, and accelerated equity vesting in specified circumstances.
- On August 4, 2021, the company granted options for 375,000 shares to the CEO, 290,000 shares to the Chief Scientific Officer, 210,000 shares to the Chief Business Officer, and 35,000 shares to the CFO. The stated exercise price was $8.87 per share.
Investor Verification Checklist
- Verify the final cash proceeds, offering expenses, and post-closing cash balance in subsequent filings.
- Review Decoy’s historical financial statements, which become the company’s accounting history after the reverse acquisition.
- Confirm the final number of shares outstanding after exercise or conversion of pre-funded warrants, warrants, options, and other securities.
- Review the terms and potential dilution from the private-placement warrants and the 2021 Stock Incentive Plan.
- Confirm whether Haskell & White LLP was formally engaged and Kesselman & Kesselman was dismissed.
- Assess preclinical development milestones, regulatory requirements, financing needs, and the absence of quantitative company guidance.